{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:31:44Z","timestamp":1792852304395,"version":"4.5.0"},"reference-count":60,"publisher":"Harborside Press, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Clinician adherence to antiemetic guidelines for preventing chemotherapy-induced nausea and vomiting (CINV) caused by highly emetogenic chemotherapy (HEC) remains poorly characterized. The primary aim of this study was to evaluate individual clinician adherence to HEC antiemetic guidelines. <jats:bold>Patients and Methods:<\/jats:bold> A retrospective analysis of patients receiving HEC was conducted using the IBM Watson Explorys Electronic Health Record Database (2012\u20132018). HEC antiemetic guideline adherence was defined as prescription of triple prophylaxis (neurokinin-1 receptor antagonist [NK1 RA], serotonin type-3 receptor antagonist, dexamethasone) at initiation of cisplatin or anthracycline + cyclophosphamide (AC). Clinicians who prescribed \u22655 HEC courses were included and individual guideline adherence was assessed, noting the number of prescribing clinicians with &gt;90% adherence. <jats:bold>Results:<\/jats:bold> A total of 217 clinicians were identified who prescribed 2,543 cisplatin and 1,490 AC courses. Patients (N=4,033) were primarily women (63.3%) and chemotherapy-na\u00efve (92%) with a mean age of 58.6 years. Breast (36%) and thoracic (19%) cancers were the most common tumor types. Guideline adherence rates of &gt;90% were achieved by 35% and 58% of clinicians using cisplatin or AC, respectively. Omission of an NK1 RA was the most common practice of nonadherence. Variation in prophylaxis guideline adherence was considerable for cisplatin (mean, 71%; SD, 29%; coefficient of variation [CV], 0.40) and AC (mean, 84%; SD, 26%; CV, 0.31). <jats:bold>Conclusions:<\/jats:bold> Findings showed substantial gaps in clinician adherence to HEC CINV guidelines, including a high variability across clinicians. Clinicians should review their individual clinical practices and ensure adherence to evidence-based CINV guidelines to optimize patient care.<\/jats:p>","DOI":"10.6004\/jnccn.2019.7526","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T19:31:47Z","timestamp":1591385507000},"page":"676-681","source":"Crossref","is-referenced-by-count":23,"title":["What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy"],"prefix":"10.6004","volume":"18","author":[{"given":"Eric J.","family":"Roeland","sequence":"first","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[{"name":"2Mayo Clinic, Rochester Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"3Duke University, Durham, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Nipp","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Binder","sequence":"additional","affiliation":[{"name":"4Helsinn Therapeutics US, Iselin, New Jersey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sebastiani","sequence":"additional","affiliation":[{"name":"5Helsinn Therapeutics, Lugano, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Potluri","sequence":"additional","affiliation":[{"name":"6SmartAnalyst, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Schmerold","sequence":"additional","affiliation":[{"name":"6SmartAnalyst, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eros","family":"Papademetriou","sequence":"additional","affiliation":[{"name":"6SmartAnalyst, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Schwartzberg","sequence":"additional","affiliation":[{"name":"7West Cancer Center, Memphis, Tennessee; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolph M.","family":"Navari","sequence":"additional","affiliation":[{"name":"8University of Alabama at Birmingham, Birmingham, Alabama."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref461","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1111\/j.1475-6773.2009.01014.x","article-title":"Geographic variation in public health spending: correlates and consequences","volume":"44","author":"Mays","year":"2009","journal-title":"Health Serv Res"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.20230","article-title":"Incidence of chemotherapy-induced nausea and emesis after modern antiemetics","volume":"100","author":"Grunberg","year":"2004","journal-title":"Cancer"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JOP.2012.000816","article-title":"Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study","volume":"10","author":"Gilmore","year":"2014","journal-title":"J Oncol Pract"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","article-title":"Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review","volume":"99","author":"Sommariva","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00520-014-2325-x","article-title":"Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers","volume":"23","author":"Van Laar","year":"2015","journal-title":"Support Care Cancer"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00520-017-3866-6","article-title":"Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses","volume":"26","author":"Clark-Snow","year":"2018","journal-title":"Support Care Cancer"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00520-015-2944-x","article-title":"Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors","volume":"24","author":"Dranitsaris","year":"2015","journal-title":"Support Care Cancer"},{"key":"ref421","first-page":"22","article-title":"Gaps in compliance with current antiemetic guidelines for highly emetogenic chemotherapy abstract Presented at the rd Conference Florida Abstract AB","volume":"23","author":"RoelandE","year":"2018","journal-title":"Annual"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","article-title":"2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy","volume":"25","author":"Herrstedt","year":"2017","journal-title":"Support Care Cancer"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study","volume":"47","author":"Molassiotis","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaoncol.2019.0086","article-title":"Treatment-related complications of systemic therapy and radiotherapy","volume":"5","author":"Jairam","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref01","first-page":"273","article-title":"Resource utilization for chemotherapy-induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens","volume":"8","author":"Schwartzberg","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"ref531","first-page":"2015","article-title":"Center to Advance Palliative Care National Palliative Care Registry Accessed Available at registry capc org","author":"January","year":"2020"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1007\/s00520-019-04730-3","article-title":"Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy","volume":"27","author":"Mahendraratnam","year":"2019","journal-title":"Support Care Cancer"},{"key":"ref431","article-title":"for Medicare Medicaid Services CMS Finalizes Hospital Outpatient Prospective Payment Changes for Accessed Available at https www cms gov newsroom fact sheets cms finalizes hospital outpatient prospective payment changes","author":"Centers","year":"2017"},{"key":"ref41","first-page":"1","article-title":"Guidelines in Version Accessed To view the most recent version visitNCCN org","volume":"14","author":"EttingerDS","year":"2020","journal-title":"Clinical Practice Oncology"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","article-title":"Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review","volume":"99","author":"Sommariva","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00520-014-2325-x","article-title":"Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers","volume":"23","author":"Van Laar","year":"2015","journal-title":"Support Care Cancer"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s00520-010-1042-3","article-title":"Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists","volume":"19","author":"Majem","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00520-012-1493-9","article-title":"The impact of chemotherapy-related nausea on patients\u2019 nutritional status, psychological distress and quality of life","volume":"21","author":"Farrell","year":"2013","journal-title":"Support Care Cancer"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00520-010-0915-9","article-title":"Impact on daily functioning and indirect\/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population","volume":"19","author":"Haiderali","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref121","article-title":"for Medicare Medicaid Services CMS Finalizes Hospital Outpatient Prospective Payment Changes for Accessed Available at https www cms gov newsroom fact sheets cms finalizes hospital outpatient prospective payment changes","author":"Centers","year":"2017"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"e654","DOI":"10.1200\/JOP.2015.005538","article-title":"Lower patient ratings of physician communication are associated with unmet need for symptom management in patients with lung and colorectal cancer","volume":"12","author":"Walling","year":"2016","journal-title":"J Oncol Pract"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","article-title":"2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy","volume":"25","author":"Herrstedt","year":"2017","journal-title":"Support Care Cancer"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaoncol.2019.0086","article-title":"Treatment-related complications of systemic therapy and radiotherapy","volume":"5","author":"Jairam","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"e654","DOI":"10.1200\/JOP.2015.005538","article-title":"Lower patient ratings of physician communication are associated with unmet need for symptom management in patients with lung and colorectal cancer","volume":"12","author":"Walling","year":"2016","journal-title":"J Oncol Pract"},{"key":"ref311","first-page":"273","article-title":"Resource utilization for chemotherapy-induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens","volume":"8","author":"Schwartzberg","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00520-012-1493-9","article-title":"The impact of chemotherapy-related nausea on patients\u2019 nutritional status, psychological distress and quality of life","volume":"21","author":"Farrell","year":"2013","journal-title":"Support Care Cancer"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study","volume":"47","author":"Molassiotis","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"ref111","first-page":"22","article-title":"Gaps in compliance with current antiemetic guidelines for highly emetogenic chemotherapy abstract Presented at the rd Conference Florida Abstract AB","volume":"23","author":"RoelandE","year":"2018","journal-title":"Annual"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","article-title":"Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting","volume":"19","author":"Burke","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","article-title":"Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting","volume":"19","author":"Burke","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1185\/03007995.2011.556603","article-title":"Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC\/MEC\/HEC)","volume":"27","author":"Schwartzberg","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12916-018-1217-1","article-title":"Practice variation in the use of tests in UK primary care: a retrospective analysis of 16 million tests performed over 3.3 million patient years in 2015\/16","volume":"16","author":"O\u2019Sullivan","year":"2018","journal-title":"BMC Med"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00520-015-2944-x","article-title":"Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors","volume":"24","author":"Dranitsaris","year":"2015","journal-title":"Support Care Cancer"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"key":"ref221","first-page":"2015","article-title":"Center to Advance Palliative Care National Palliative Care Registry Accessed Available at registry capc org","author":"January","year":"2020"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1007\/s00520-019-04730-3","article-title":"Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy","volume":"27","author":"Mahendraratnam","year":"2019","journal-title":"Support Care Cancer"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00520-017-3866-6","article-title":"Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses","volume":"26","author":"Clark-Snow","year":"2018","journal-title":"Support Care Cancer"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"294","DOI":"10.6004\/jnccn.2017.7043","article-title":"Ten-year trends in antiemetic prescribing in patients receiving highly emetogenic chemotherapy","volume":"16","author":"O\u2019Sullivan","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"ref351","first-page":"1","article-title":"Guidelines in Version Accessed To view the most recent version visitNCCN org","volume":"14","author":"EttingerDS","year":"2020","journal-title":"Clinical Practice Oncology"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1111\/j.1475-6773.2009.01014.x","article-title":"Geographic variation in public health spending: correlates and consequences","volume":"44","author":"Mays","year":"2009","journal-title":"Health Serv Res"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JOP.2012.000816","article-title":"Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study","volume":"10","author":"Gilmore","year":"2014","journal-title":"J Oncol Pract"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12916-018-1217-1","article-title":"Practice variation in the use of tests in UK primary care: a retrospective analysis of 16 million tests performed over 3.3 million patient years in 2015\/16","volume":"16","author":"O\u2019Sullivan","year":"2018","journal-title":"BMC Med"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00520-010-0915-9","article-title":"Impact on daily functioning and indirect\/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population","volume":"19","author":"Haiderali","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s00520-010-1042-3","article-title":"Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists","volume":"19","author":"Majem","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"294","DOI":"10.6004\/jnccn.2017.7043","article-title":"Ten-year trends in antiemetic prescribing in patients receiving highly emetogenic chemotherapy","volume":"16","author":"O\u2019Sullivan","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1185\/03007995.2011.556603","article-title":"Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC\/MEC\/HEC)","volume":"27","author":"Schwartzberg","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.20230","article-title":"Incidence of chemotherapy-induced nausea and emesis after modern antiemetics","volume":"100","author":"Grunberg","year":"2004","journal-title":"Cancer"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/6\/article-p676.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/18\/6\/article-p676.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T18:41:29Z","timestamp":1592592089000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/6\/article-p676.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":60,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2019.7526","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}